Short-term signal: Michael Kors Holdings Limited (KORS)

Sep 19, 2017
Jimmy Choo said its shareholders approved the $1.2 billion takeover by Michael Kors
Read more
Why Bullish? Michael Kors plans to expand the fashion innovation in its accessories assortments, elevate the brand’s store experience, and treat fiscal 2018 as a transition year in which the company establishes a new baseline before returning to long-term growth. Therefore, will impact the stock in today trade and up to 2-14

Latest price: 44.65
Entry level: 45.9
Exit level: 49.2
Stop level: 44.8

About the company
Michael Kors Holdings Limited design, markets, distributes, and retails branded women’s apparel and accessories, and men’s apparel. The company operates in three segments: Retail, Wholesale, and Licensing.

finviz dynamic chart for  kors

(Views and recommendations given in this section are for research purpose only. Please consult your financial adviser before taking any position in the stock/s mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers

Short-term signal: Pluristem Therapeutics Inc. (PSTI)

Sep 18, 2017
Pluristem stock jumps after FDA grants CLI treatment fast-track designation
Read more
Why Bullish? five to six million people in the U.S. and Europe suffer from CLI, and the number is expected to grow as more patients get diabetes. Therefore, will impact the stock in today trade and up to 2-14

Latest price: 1.34
Entry level: 1.52
Exit level: 1.63
Stop level: 1.48

About the company
Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions

finviz dynamic chart for  PSTI

(Views and recommendations given in this section are for research purpose only. Please consult your financial adviser before taking any position in the stock/s mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers

Short-term signal: Halozyme Therapeutics, Inc. (HALO)

Sep 14, 2017
Bristol is teaming up with Halozyme to test its immuno-oncology drugs as injections using Halozyme’s technology
Read more
Why Bullish? Halozyme will receive a $105 million upfront payment as well as future milestones and royalties. Therefore, will impact the stock in today trade and up to 2-14

Latest price: 13.18
Entry level: 14.8
Exit level: 15.6
Stop level: 14.1

About the company
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.

finviz dynamic chart for  halo

(Views and recommendations given in this section are for research purpose only. Please consult your financial adviser before taking any position in the stock/s mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers

Short-term signal: Centene Corporation (CNC)

Sep 13, 2017
Centene up sharply after $3.75B acquisition of Fidelis in NY.
Read more
Why Bullish? the buyout will set a stock rally. Therefore, will impact the stock in today trade and up to 2-14

Latest price: 90.88
Entry level: 95.3
Exit level: 99.8
Stop level: 93.2

About the company
Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States.

finviz dynamic chart for  cnc

(Views and recommendations given in this section are for research purpose only. Please consult your financial adviser before taking any position in the stock/s mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers

Short-term signal: Quotient Limited (QTNT)

Sep 12, 2017
Quotient Limited Reports Results From Latest MosaiQ Performance Evaluation Studies Prior to Commencing Verification and Validation Studies
Read more
Why Bullish? Quotient has commenced the commercialization of MosaiQ in Europe, where it has already received invitations to participate in tenders to be awarded in the middle of CY18. Therefore, will impact the stock in today trade and up to 2-14

Latest price: 3.71
Entry level: 4.3
Exit level: 4.58
Stop level: 4.2

About the company
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide

finviz dynamic chart for  qtnt

(Views and recommendations given in this section are for research purpose only. Please consult your financial adviser before taking any position in the stock/s mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers

Short-term signal: Teva Pharmaceutical Industries Limited (TEVA)

Sep 11, 2017
Israel’s Teva Pharma appoints Lundbeck’s Kare Schultz as CEO
Read more
Why Bullish? Schultz had been widely experienced at the world’s largest diabetes drugmaker Novo Nordisk before stepping down in 2015 when Novo’s former CEO said he would stay until 2019. Therefore, will impact the stock in today trade and up to 2-14 days.

Latest price: 15.5
Entry level: 17.1
Exit level: 18.4
Stop level: 16.2

About the company
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide

finviz dynamic chart for  teva

(Views and recommendations given in this section are for research purpose only. Please consult your financial adviser before taking any position in the stock/s mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers